Sandoz Plugs Ophthalmology Gap With Coherus Ranibizumab Deal
Deal Includes $170m Upfront; Coherus Pushing Into Novel Oncology Space
Sandoz has truly spread its wings since separating from Novartis, striking its first post-spinoff acquisition agreement by taking the Lucentis biosimilar Cimerli from Coherus BioSciences, which is moving in a different strategic direction.
